Analyst Price Targets — KRYS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 12:56 pm | Geulah Livshits | Chardan Capital | $323.00 | $282.65 | TheFly | Krystal Biotech price target raised to $323 from $220 at Chardan |
| February 17, 2026 6:26 pm | Roger Song | Jefferies | $371.00 | $291.10 | TheFly | Krystal Biotech price target raised to $371 from $310 at Jefferies |
| January 30, 2026 12:31 pm | — | Goldman Sachs | $327.00 | $279.34 | TheFly | Krystal Biotech price target raised to $327 from $206 at Goldman Sachs |
| January 9, 2026 11:08 am | — | H.C. Wainwright | $310.00 | $248.91 | TheFly | Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright |
| October 17, 2025 10:44 am | Debjit Chattopadhyay | Guggenheim | $224.00 | $188.33 | TheFly | Krystal Biotech price target raised to $224 from $189 at Guggenheim |
| August 22, 2025 12:03 pm | — | Chardan Capital | $216.00 | $150.49 | TheFly | Krystal Biotech price target lowered to $216 from $219 at Chardan |
| September 11, 2024 6:53 am | Dae Gon Ha | Stifel Nicolaus | $220.00 | $185.00 | TheFly | Krystal Biotech price target raised to $220 from $204 at Stifel |
| September 2, 2024 7:20 am | Alec Stranahan | Bank of America Securities | $205.00 | $195.12 | TheFly | Krystal Biotech price target raised to $205 from $195 at BofA |
| August 12, 2024 8:23 am | Gavin Clark-Gartner | Evercore ISI | $206.00 | $182.17 | TheFly | Krystal Biotech price target raised to $206 from $201 at Evercore ISI |
| April 15, 2024 4:25 pm | Dae Gon Ha | Stifel Nicolaus | $204.00 | $169.75 | StreetInsider | Krystal Biotech (KRYS) PT Raised to $204 at Stifel |
Latest News for KRYS
All three drugmakers have proven fairly innovative in their respective niches. Clinical and commercial progress could send their share prices soaring.
Krystal Biotech has attractive prospects within its core market. The biotech could launch more products in the next few years.
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech position increased by $50.33 million, reflecting both trading and price movement effects.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KRYS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.